PubMed · 3817616
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A P Corcos, R Friedmann, Y Lysy, I Chowers. 1986-11-16. [Dawn phenomenon].. https://pubmed.ncbi.nlm.nih.gov/3817616/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
We have determined the glucose concentration of whole blood from mid-infrared spectra without sample preparation or use of chemical reagents. We selected 1119-1022 cm(-1) as the optimal wavelength range for our measurement by making a first-loading vector analysis based on partial least-squares regression. We examined the influence of hemoglobin on samples by using different calibration and prediction sets. The accuracy of glucose prediction depended on the hemoglobin level in the calibration model; the sample set should represent the entire range of hemoglobin concentration. We obtained an accuracy of 5.9% in glucose prediction, and this value is well within a clinically acceptable range.
Explore the source record for details and available documents.
Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intestinal mucosa and released in response to a meal, is essential for normal glucose homoeostasis. There is much interest in the use of GLP-1 to treat diabetes, since the risk of hypoglycaemia is thought to be low. We report an instance of a 45-year-old woman with a GLP-1 and somatostatin secreting neuroendocrine tumour who presented with reactive hypoglycaemia and hyperglycaemia, but who was subsequently cured by surgery. This case, of a neuroendocrine tumour secreting GLP-1 and causing reactive hypoglycaemia, indicates a potential adverse effect of GLP-1 therapy for diabetes.